Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H7O3.Na |
Molecular Weight | 126.0863 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].OCCCC([O-])=O
InChI
InChIKey=XYGBKMMCQDZQOZ-UHFFFAOYSA-M
InChI=1S/C4H8O3.Na/c5-3-1-2-4(6)7;/h5H,1-3H2,(H,6,7);/q;+1/p-1
Molecular Formula | C4H7O3 |
Molecular Weight | 103.0966 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of neurotransmitters that are co-localised with GHB. After exogenous administration, most of the observed behavioural effects appear to be mediated via the activity of GHB at GABA(B) receptors, as long as the concentration is sufficient to elicit binding, which does not happen at endogenous concentrations. Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness (EDS) in narcolepsy.
CNS Activity
Originator
Sources: Laborit H. (1964) Sodium 4-hydroxybutyrate. J Neuropharmacol 32: 433–452
Curator's Comment: Sodium oxybate (sodium salt of gamma-hydroxybutyrate (GHB) was first described as a possible precursor of GABA that could cross the blood-brain barrier [Laborit, 1964]. Further elucidation proved it an endogenous metabolite of GABA [Roth and Giarman, 1969] with a turnover of 0.16% of GABA being converted to GHB [Maitre, 1997] reference retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382678/
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf |
100.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | XYREM Approved UseXYREM® (sodium oxybate) oral solution is a central nervous system depressant indicated for the treatment of:
• Cataplexy in narcolepsy
• Excessive daytime sleepiness (EDS) in narcolepsy Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3122 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
1271 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1565 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
905 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
22 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Diagnosis of unsuspected gamma hydroxy-butyrate poisoning by proton NMR. | 2001 |
|
The effect of gamma hydroxybutyrate on serum osmolality. | 2001 |
|
New developments in the pharmacotherapy of alcohol dependence. | 2001 |
|
Alteration of GLUR2 expression in the rat brain following absence seizures induced by gamma-hydroxybutyric acid. | 2001 Apr |
|
Procedure of bidirectional selective outbreeding for production of two rat lines differing in sensitivity to the sedative/hypnotic effect of gamma-hydroxybutyric acid. | 2001 Aug |
|
[The new drugs: ecstasy, GHB. Update for practitioners]. | 2001 Dec |
|
[Gamma hydroxy butyrate intoxication]. | 2001 Dec |
|
Drug use and sexual risk behavior among gay and bisexual men who attend circuit parties: a venue-based comparison. | 2001 Dec 1 |
|
Lack of genetic differentiation among widely spaced subpopulations of a butterfly with home range behaviour. | 2001 Feb |
|
First derivative spectrophotometric, TLC-densitometric, and HPLC determination of acebutolol HCL in presence of its acid-induced degradation product. | 2001 Feb |
|
A model of atypical absence seizures: EEG, pharmacology, and developmental characterization. | 2001 Feb 13 |
|
Adverse events, including death, associated with the use of 1,4-butanediol. | 2001 Jan 11 |
|
Expression of a glutamate decarboxylase homologue is required for normal oxidative stress tolerance in Saccharomyces cerevisiae. | 2001 Jan 5 |
|
Multivariate curve resolution of wavelet and Fourier compressed spectra. | 2001 Jul 15 |
|
Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. | 2001 Jul 20 |
|
Characterization of partially transesterified poly(beta-hydroxyalkanoate)s by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | 2001 Jul-Aug |
|
Response to the presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fluids. | 2001 Jul-Aug |
|
GHB: a new and novel drug of abuse. | 2001 Jun 1 |
|
Identification and effects of interaction phytotoxic compounds from exudate of Cistus ladanifer leaves. | 2001 Mar |
|
The urinary excretion of gamma-hydroxybutyric acid in man. | 2001 Mar |
|
GHB: its use and misuse. | 2001 Mar |
|
Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma. | 2001 Mar |
|
The content and distribution of troponin I, troponin T, myoglobin, and alpha-hydroxybutyric acid dehydrogenase in the human heart. | 2001 May |
|
A case of severe withdrawal from gamma-hydroxybutyrate. | 2001 May |
|
GHB: an important pharmacologic and clinical update. | 2001 May-Aug |
|
Drug dependence studies and regulations: an overview of the past and present. | 2001 Nov |
|
The chemical interconversion of GHB and GBL: forensic issues and implications. | 2001 Nov |
|
Traumatic brain injury after a motor vehicle accident: fact or "fantasy"? | 2001 Nov |
|
Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice. | 2001 Nov |
|
Management of gamma-hydroxybutyrate withdrawal. | 2001 Nov |
|
Window of detection of gamma-hydroxybutyrate in blood and saliva. | 2001 Nov |
|
A contemporaneous finding of fenproporex in a polydrug suicide. | 2001 Oct |
|
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. | 2001 Oct |
|
Role of GABA(B) receptors in the sedative/hypnotic effect of gamma-hydroxybutyric acid. | 2001 Oct 12 |
|
GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. | 2001 Oct 15 |
|
[Well-documented information on GHB]. | 2001 Oct 3 |
|
Drugs, drink'n and smok'n. Part II. | 2001 Sep |
|
Use of physostigmine in the management of gamma-hydroxybutyrate overdose. | 2001 Sep |
|
Two cases of withdrawal from 1,4-Butanediol use. | 2001 Sep |
|
Using the overlapping parts of laboratory test panels to evaluate abnormal results. | 2001 Summer |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf
Initiate dose at 4.5 grams (g) per night administered orally in two equal, divided doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later.
Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later).
Recommended dose range: 6 g to 9 g per night orally.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11313294
Curator's Comment: gamma-hydroxybutyrate (GHB) activates both pre- and postsynaptic GABA(B)-receptors in neocortical neurons participating in fast synaptic transmission, leading to a powerful depression of neocortical network activity.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:23:00 GMT 2023
by
admin
on
Fri Dec 15 15:23:00 GMT 2023
|
Record UNII |
7G33012534
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
XYREM (AUTHORIZED: NARCOLEPSY)
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
WHO-VATC |
QN01AX11
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
WHO-VATC |
QN07XX04
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
XYREM (AUTHORIZED: CATAPLEXY)
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
WHO-ATC |
N01AX11
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
WHO-ATC |
N07XX04
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/02/131
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
NCI_THESAURUS |
C2199
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
NDF-RT |
N0000175758
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
DEA NO. |
2012
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
||
|
FDA ORPHAN DRUG |
530216
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
D012978
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
7G33012534
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
84223
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
7G33012534
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
SODIUM OXYBATE
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL1342
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
90318-49-3
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
9899
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
502-85-2
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
30830
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
Sodium Oxybate
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
23663870
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
m6124
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB09072
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
207-953-3
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
DTXSID3048940
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
100000089135
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
SUB14731MIG
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
4566
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
502-85-2
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
C61870
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY | |||
|
SUB60580
Created by
admin on Fri Dec 15 15:23:00 GMT 2023 , Edited by admin on Fri Dec 15 15:23:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
LABELED -> NON-LABELED |
|
||
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|